Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19 | Cerebrovascular Disease | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Diagnosis, Management, and Pathophysiology of Arterial and Venous Thrombosis in COVID-19

Educational Objective
To identify the key insights or developments described in this article
1 Credit CME

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

CME Disclosure Statement: Unless noted, all individuals in control of content reported no relevant financial relationships. If applicable, all relevant financial relationships have been mitigated.

Article Information

Corresponding Author: Gregory Piazza, MD, MS, Division of Cardiovascular Medicine, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (gpiazza@partners.org).

Published Online: November 23, 2020. doi:10.1001/jama.2020.23422

Conflict of Interest Disclosures: Dr Piazza reported receiving grants from Bristol Myers Squibb, Janssen, Boston Scientific Corporation, Portola, and Bayer and personal fees from the Prairie Education and Research Cooperative, Amgen, Pfizer, and Agile outside the submitted work. Dr Morrow reported receiving grants from Abbott Laboratories, Amgen, Anthos Therapeutics, Esai, GlaxoSmithKline, Takeda, and The Medicines Company; grants and personal fees from AstraZeneca, Merck, Novartis, and Roche Diagnostics; and personal fees from Bayer Pharma and InCarda outside the submitted work and being a member of the TIMI Study Group, which has received institutional research grant support through Brigham and Women's Hospital from Abbott, Amgen, Anthos Therapeutics, Aralez, AstraZeneca, Bayer HealthCare Pharmaceuticals Inc, Daiichi-Sankyo, Eisai, GlaxoSmithKline, Intarcia, Janssen, MedImmune, Merck, Novartis, Pfizer, Poxel, Quark Pharmaceuticals, Regeneron, Roche, Siemens, Takeda, The Medicines Company, and Zora Biosciences.

References
1.
Piazza  G , Campia  U , Hurwitz  S ,  et al.  Registry of arterial and venous thromboembolic complications in patients with COVID-19.   J Am Coll Cardiol. 2020;76(18):2060-2072. doi:10.1016/j.jacc.2020.08.070PubMedGoogle ScholarCrossref
2.
Fox  SE , Akmatbekov  A , Harbert  JL , Li  G , Quincy Brown  J , Vander Heide  RS .  Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans.   Lancet Respir Med. 2020;8(7):681-686. doi:10.1016/S2213-2600(20)30243-5PubMedGoogle ScholarCrossref
3.
Zhang  Y , Cao  W , Jiang  W ,  et al.  Profile of natural anticoagulant, coagulant factor and anti-phospholipid antibody in critically ill COVID-19 patients.   J Thromb Thrombolysis. 2020;50(3):580-586. doi:10.1007/s11239-020-02182-9PubMedGoogle ScholarCrossref
4.
Zaid  Y , Puhm  F , Allaeys  I ,  et al.  Platelets can associate with SARS-Cov-2 RNA and are hyperactivated in COVID-19.   Circ Res. 2020. doi:10.1161/CIRCRESAHA.120.317703PubMedGoogle Scholar
5.
Nicolai  L , Leunig  A , Brambs  S ,  et al.  Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy.   Circulation. 2020;142(12):1176-1189. doi:10.1161/CIRCULATIONAHA.120.048488PubMedGoogle ScholarCrossref
6.
Ackermann  M , Verleden  SE , Kuehnel  M ,  et al.  Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19.   N Engl J Med. 2020;383(2):120-128. doi:10.1056/NEJMoa2015432PubMedGoogle ScholarCrossref
7.
Lodigiani  C , Iapichino  G , Carenzo  L ,  et al; Humanitas COVID-19 Task Force.  Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy.   Thromb Res. 2020;191:9-14. doi:10.1016/j.thromres.2020.04.024PubMedGoogle ScholarCrossref
8.
Roberts  LN , Whyte  MB , Georgiou  L ,  et al.  Postdischarge venous thromboembolism following hospital admission with COVID-19.   Blood. 2020;136(11):1347-1350. doi:10.1182/blood.2020008086PubMedGoogle ScholarCrossref
9.
Moores  LK , Tritschler  T , Brosnahan  S ,  et al  Prevention, diagnosis and treatment of venous thromboembolism in patients with COVID-19: CHEST Guideline and Expert Panel Report.   Chest. 2020;158:1143-1163. doi:10.1016/j.chest.2020.05.559PubMedGoogle ScholarCrossref
10.
Spyropoulos  AC , Levy  JH , Ageno  W ,  et al; Subcommittee on Perioperative, Critical Care Thrombosis, Haemostasis of the Scientific, Standardization Committee of the International Society on Thrombosis and Haemostasis.  Scientific and Standardization Committee communication: Clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19.   J Thromb Haemost. 2020;18(8):1859-1865. doi:10.1111/jth.14929PubMedGoogle ScholarCrossref
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close